Literature DB >> 10543764

In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.

R Schaumann1, G Ackermann, B Pless, M C Claros, A C Rodloff.   

Abstract

The activity of the new fluoroquinolone gatifloxacin was compared with those of other quinolones and antimicrobial agents of other classes against 294 anaerobes by the broth microdilution technique. For all strains tested, gatifloxacin MICs at which 50 and 90% of the isolates were inhibited were 0.5 and 2 mg/liter, respectively, and were 3 to 4 dilution steps lower than, e.g., ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543764      PMCID: PMC89560     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.

Authors:  E J Goldstein; D M Citron; C V Merriam; K Tyrrell; Y Warren
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

3.  In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.

Authors:  M Hosaka; T Yasue; H Fukuda; H Tomizawa; H Aoyama; K Hirai
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

4.  Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

5.  Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.

Authors:  H Tomioka; H Saito; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

6.  Antibacterial properties of AM-1155, a new 8-methoxy quinolone.

Authors:  M Hosaka; S Kinoshita; A Toyama; M Otsuki; T Nishino
Journal:  J Antimicrob Chemother       Date:  1995-08       Impact factor: 5.790

7.  In vitro activity of DU-6859a against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Reeves; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

8.  In vitro activity of Bay Y3118 against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

9.  In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae.

Authors:  K Ishida; M Kaku; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; K Tomono; N Suyama
Journal:  J Antimicrob Chemother       Date:  1994-12       Impact factor: 5.790

10.  German multicentre study on the in vitro susceptibility of Bacteroides species. The German Bacteroides Study Group.

Authors:  A C Rodloff; H Werner; M Kresken; A Jansen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

View more
  9 in total

1.  Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate.

Authors:  Andrej Trampuz; Gerd Laifer; Markus Wenk; Zarko Rajacic; Werner Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone.

Authors:  Kaori Tanaka; Hiroshige Mikamo; Ken'ichi Nakao; Kunitomo Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

3.  In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.

Authors:  Reiner Schaumann; Matthias Funke; Eva Janssen; Arne C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

Review 4.  Gatifloxacin: a review of its use in the management of bacterial infections.

Authors:  Caroline M Perry; Douglas Ormrod; Miriam Hurst; Susan V Onrust
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Bacteroides fragilis group: trends in resistance.

Authors:  Manfred Fille; Monica Mango; Matthias Lechner; Reiner Schaumann
Journal:  Curr Microbiol       Date:  2006-01-31       Impact factor: 2.188

7.  The Role of Fluoroquinolones in the Treatment of Skin and Soft Tissue Infection.

Authors:  Md Rabiul Alam; Ellie Hershberger; Marcus J. Zervos
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

8.  In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.

Authors:  A Liebetrau; A C Rodloff; J Behra-Miellet; L Dubreuil
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  Oxidative stress induced by fluoroquinolones on treatment for complicated urinary tract infections in Indian patients.

Authors:  V Talla; Pr Veerareddy
Journal:  J Young Pharm       Date:  2011-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.